Golden Throat Holdings Group Co Ltd (6896) AI Stock Analysis

• Market Cap: HK$2.31B
• Dividend Yield: 15.97%
• Average Volume (3M): 691.97K
• Price to Earnings (P/E): 8.0
• Beta (1Y): 0.16
• Revenue Growth: -2.70%
• EPS Growth: 2.19%
• Country: HK
• Employees: 874
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.12
• Shares Outstanding: 739,302,000
• 10 Day Avg. Volume: 656,610
• 30 Day Avg. Volume: 691,973
• PEG Ratio: 0.27
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 1.90
• P/FCF Ratio: 5.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: HK$4.00 ▲(30.29% Upside)

Golden Throat Holdings demonstrates strong financial performance with robust revenue growth and profitability, supported by a stable balance sheet. The valuation is attractive with a low P/E ratio and high dividend yield, making it appealing for value and income investors. However, technical indicators suggest mixed market momentum, which could pose short-term challenges.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Profitability Margins

High profitability margins suggest efficient cost management and pricing power, enhancing financial resilience and competitive positioning.

Balance Sheet Health

A strong balance sheet with low leverage provides financial stability and flexibility to pursue growth opportunities and withstand economic downturns.

Negative Factors

Profit Warning

The anticipated profit decline reflects challenges in adapting to industry changes, potentially impacting future earnings and market confidence.

Cash Flow Concerns

Lack of current cash flow data raises concerns about liquidity management and the ability to fund operations and investments sustainably.

Industry Changes

Industry shifts and strategic adjustments may require significant adaptation, posing risks to market position and future profitability.

Golden Throat Holdings Group Co Ltd Business Overview & Revenue Model

Company Description

Golden Throat Holdings Group Company Limited, an investment holding company, manufactures and sells pharmaceutical, healthcare food, and other products in the People's Republic of China. It offers Golden Throat lozenges over-the-counter medicine to relive symptoms of sore and dry throat, and hoarse voice caused by acute pharyngitis. It also provides Golden Throat lozenge series products that include Dule lozenges and sugar-free Dule lozenges in various flavors, such as orange, fructus momordicae, chrysanthemum, American ginseng, and hawthorn; Yinxingye tablet, which is designed to facilitate blood circulation, remove blood stasis, and dredge energy channels; and herbal vegetable beverages for soothing voice and relieving sore throats. The company also exports its products to the United States, Canada, Russia, the European Union, Australia, Southeast Asia, the Middle East, Mexico, and Africa. Golden Throat Holdings Group Company Limited was founded in 1956 and is headquartered in Liuzhou, the People's Republic of China.

How the Company Makes Money

Golden Throat Holdings Group Co Ltd generates revenue through multiple streams, predominantly from the sale of its diverse product lines in the food and beverage sector. The company capitalizes on its strong brand recognition and distribution network to reach consumers across various channels, including retail, online platforms, and food service establishments. Key revenue streams include direct sales of bottled beverages, herbal teas, and other health-oriented products. Additionally, the company may engage in strategic partnerships with distributors and retailers to expand its market reach and enhance product visibility. Factors contributing to its earnings include effective marketing strategies, consumer trends favoring healthier beverage options, and ongoing investment in product development to meet evolving consumer preferences.

Golden Throat Holdings Group Co Ltd Financial Statement Overview

Summary

Golden Throat Holdings showcases robust financial health with strong revenue growth, high profitability margins, and a stable balance sheet. Despite concerns about the lack of operating cash flow data for 2024, the company’s historical cash generation capacity and low leverage underscore its financial resilience and potential for continued growth.

Income Statement

Golden Throat Holdings has demonstrated strong revenue growth, with a 23.3% increase from 2023 to 2024, and maintained robust profitability with a gross profit margin of 75.5% and a net profit margin of 26.9% for 2024. The company's EBIT and EBITDA margins are also solid at 32.8% and 38.5%, respectively, indicating efficient operations and strong earnings before interest and taxes.

Balance Sheet

The company exhibits a healthy balance sheet with a low debt-to-equity ratio of 0.29, highlighting conservative leverage. Additionally, the return on equity is impressive at 21.7%, reflecting efficient use of shareholder funds. The equity ratio of 65.1% further indicates a strong equity base relative to total assets, suggesting financial stability.

Cash Flow

Although the free cash flow in 2024 is not available, the company previously generated positive free cash flow in 2023, which grew by 90.3% from 2022 to 2023. However, the absence of operating cash flow in 2024 is a concern, as it limits the ability to assess current cash generation efficiency relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	979.71M	1.19B	961.38M	992.01M	820.54M	646.94M
Gross Profit	748.65M	894.18M	697.72M	720.92M	577.74M	475.64M
EBITDA	373.17M	456.65M	410.75M	424.93M	281.80M	233.31M
Net Income	268.11M	318.63M	250.16M	281.22M	187.64M	154.05M
Balance Sheet
Total Assets	2.12B	2.25B	2.30B	2.30B	1.95B	1.69B
Cash, Cash Equivalents and Short-Term Investments	1.06B	1.14B	1.07B	925.51M	802.84M	705.54M
Total Debt	684.03M	426.92M	412.34M	272.59M	235.00M	152.45M
Total Liabilities	914.07M	784.87M	748.34M	760.18M	588.04M	464.75M
Stockholders Equity	1.21B	1.47B	1.55B	1.54B	1.37B	1.22B
Cash Flow
Free Cash Flow	185.70M	408.65M	221.30M	255.30M	116.23M	83.80M
Operating Cash Flow	238.09M	475.87M	238.84M	271.15M	164.89M	167.75M
Investing Cash Flow	-12.19M	-41.60M	-59.67M	36.59M	-145.11M	-81.26M
Financing Cash Flow	-87.37M	-335.18M	-79.38M	-142.01M	-10.21M	49.36M

Golden Throat Holdings Group Co Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6896, the sentiment is Negative. The current price of 3.07 is below the 20-day moving average (MA) of 3.13, below the 50-day MA of 3.29, and below the 200-day MA of 3.87, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 42.62 is Neutral, neither overbought nor oversold. The STOCH value of 47.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6896.

Golden Throat Holdings Group Co Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6896	75 Outperform	HK$2.31B	7.96	21.47%	15.97%	-2.70%	2.19%
2161	75 Outperform	HK$2.28B	10.43	20.78%	9.98%	12.83%	36.12%
2877	73 Outperform	HK$7.05B	7.90	10.85%	5.80%	-20.64%	-25.39%
2348	72 Outperform	HK$1.80B	9.47	5.34%	5.16%	2.89%	-68.83%
3737	68 Neutral	HK$745.36M	33.46	1.87%	9.43%	-1.99%	-81.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1498	41 Neutral	HK$187.23M	-3.59	-33.22%	―	-17.32%	55.74%

Golden Throat Holdings Group Co Ltd Corporate Events

Golden Throat Tightens Nomination Committee Rules to Boost Governance and Board Diversity

Golden Throat Holdings Group Company Limited has updated the terms of reference for its Board Nomination Committee, originally adopted in 2015 and now revised as of 24 December 2025. The revised framework formalises the committee’s composition, requiring at least three directors with a majority of independent non-executive directors, mandates at least one director of a different gender, and sets out rules on appointment of the committee chairman and secretary, tenure aligned with the company’s articles, and meeting quorum. These governance changes aim to strengthen the company’s board nomination process, enhance diversity and independence in board appointments, and align with Hong Kong listing requirements, potentially improving oversight and confidence among investors and other stakeholders.

The most recent analyst rating on (HK:6896) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Golden Throat Holdings Group Co Ltd stock, see the HK:6896 Stock Forecast page.